thiorphan has been researched along with Diabetic Cardiomyopathies in 2 studies
Thiorphan: A potent inhibitor of membrane metalloendopeptidase (ENKEPHALINASE). Thiorphan potentiates morphine-induced ANALGESIA and attenuates naloxone-precipitated withdrawal symptoms.
Diabetic Cardiomyopathies: Diabetes complications in which VENTRICULAR REMODELING in the absence of CORONARY ATHEROSCLEROSIS and hypertension results in cardiac dysfunctions, typically LEFT VENTRICULAR DYSFUNCTION. The changes also result in myocardial hypertrophy, myocardial necrosis and fibrosis, and collagen deposition due to impaired glucose tolerance.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Malek, V | 2 |
| Sharma, N | 1 |
| Gaikwad, AB | 2 |
2 other studies available for thiorphan and Diabetic Cardiomyopathies
| Article | Year |
|---|---|
Simultaneous inhibition of neprilysin and activation of ACE2 prevented diabetic cardiomyopathy.
Topics: Angiotensin-Converting Enzyme 2; Animals; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 1 | 2019 |
Telmisartan and thiorphan combination treatment attenuates fibrosis and apoptosis in preventing diabetic cardiomyopathy.
Topics: Acetylation; Angiotensin II Type 1 Receptor Blockers; Animals; Apoptosis; Diabetes Mellitus, Experim | 2019 |